๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS ยท Real-Time Price ยท USD
26.58
-0.64 (-2.35%)
At close: Nov 20, 2026, 4:00 PM EST
26.76
+0.18 (0.68%)
After-hours: Nov 20, 2026, 7:59 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

TRYNGOLZA is building a new sHTG market, with launch priorities focused on high-risk patients, physician experience and smoother access. By end-September, 34% of commercial lives were covered and more than 1,500 prescribers had written prescriptions.

Albert Zhang
Associate, Jefferies

Hello, everyone. Welcome to Jefferies Global Healthcare conference. My name is Albert Zhang. I am an Associate on Akash Tewari's team. Akash is running a little late from another meeting, but we have the pleasure here to have Dr. Brett Monia. Akash is here.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

I am sorry about that. Thank you, Albert. Brett, great to have you, and apologies for the lateness. Really looking forward to the discussion. Why do I hand it off to you for some intro remarks, and we will get started?

Brett Monia
CEO, Ionis

Yeah. Happy to, Akash. Thanks, everybody. Thank you for the invitation. Great to see all of you. We are really excited about the future value creation potential for Ionis going forward. Ionis is completing the evolution to a fully integrated commercial stage biotechnology company, launching our own medicines. We are now in the process of launching three really important medicines wholly owned by Ionis today, products that have been approved just over the last one or two years. TRYNGOLZA for severe hypertriglyceridemia for a multi-billion dollar market opportunity. DAWNZERA for hereditary angioedema, a rare disease indication. That launch continues to go very well. Just recently, approval for a neurodegenerative indication called Alexander disease, ZANVASTRO, for that disease. That launch is now underway, being conducted by Ionis. Today, we have seven products on the market, including those three, for eight disease indications.

We have four medicines in phase III development, and with more expected to reach phase III development next year, setting us up for a steady cadence of new medicines reaching the market, all of which have real breakthrough profiles for patients, for shareholders, and so on. Ionis is very well-positioned to deliver a steady cadence of medicines to drive value well into the future.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Understood. Brett, let's start off with TRYNGOLZA, and I think there's a lot of investor attention on that. Surprising quarter sometimes, the surprises are good, sometimes they're bad. I want to start off with a question that almost sounds absurd sometimes, where you're like, but we get it a lot, and we think about it, which is this a, quote unquote, "real market"? I think there's more nuance to that. It's more, is there enough urgency to really drive physician engagement out of the gate? Do doctors look at TGs and say, "You know what? I've looked at this for a while. I'm not urgently looking at treating this." And how do you kind of narrow the scope to really identify people who are urgently going to get patients on TRYNGOLZA and convert them into kind of paid scripts?

I think you've learned more about the market too as you've entered. So, what have you thought about initially, and how have you refined that as you've entered into the market?

Brett Monia
CEO, Ionis

Happy to. Let me level set for everybody first of all. TRYNGOLZA is indicated today for two diseases. One is familial chylomicronemia syndrome. That was launched last year, and that launch went off as a rare disease, and that launch has gone very well. This year, we expanded the indication for severe hypertriglyceridemia, which is not a rare disease. It affects millions of people with high triglycerides that are well above normal that put them at high risk for various comorbidities, but most importantly is the risk of a potentially fatal acute pancreatitis attack. And if it's not fatal, at least the destruction of the pancreas and all kinds of problems, diabetes and so on.

TRYNGOLZA is the first FDA-approved medicine, now approved in Europe as of yesterday, for severe hypertriglyceridemia that not only has unprecedented reductions in triglycerides, but also for the first time demonstrating statistically significant reductions in acute pancreatitis. So, it has outcome data. This affects, as I think I said, millions of people in major markets. What we're focused on, Akash, of course, are initially are those high-risk patients, which are about 1 million in the U.S. and probably equal in Europe, that are at high risk for acute pancreatitis because their triglycerides are so high that they're at higher risk, or they have already had acute pancreatitis events. And once you've had one event, the chances of a recurring potentially fatal event increases exponentially.

That's been our initial focus. Your question is whether this is a real market or not, is you said, I won't say the word. You said absurd.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

It's an absurd question.

Brett Monia
CEO, Ionis

I think it's obvious that.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Yeah.

Brett Monia
CEO, Ionis

I think that's the opinion of HCPs as well around the globe, that this is a very, very high unmet medical need, and TRYNGOLZA is the first medicine to meaningfully address this disease indication. Now, we're in the early innings of the launch. We're three months into a launch. We're creating a new category, right? That requires extensive education, that requires HCPs to become familiar with a brand new medicine that they probably don't have much familiarity unless they were prescribing for FCS in the past. It requires them to be educated on what are the criteria for prescribing their drug to patients, you know, the drug. Do they have to be on another triglyceride-lowering generic drug first? Will they got to get their triglycerides measured?

Will the access process be easy, smooth, streamlined for them so that they don't have headaches and their office staff doesn't get blocked up with having to go through medical exceptions and those kinds of things? We're working through all that right now. What I can tell you is that we are 100% confident in the multi-billion dollar product opportunity for TRYNGOLZA, and that's based on tremendous HCP enthusiasm with intent to treat patients, a remarkably broad label that includes reductions in acute pancreatitis in the indication statement, despite the fact that that wasn't our primary endpoint. The FDA recognized that as being so important that they put it in the indication statement.

What has been the biggest surprise to your part of your question, in the early part of the launch, three months into the launch only, I want to emphasize that, is that although there's been tremendous enthusiasm by the HCP community, particularly cardiologists, with intent to treat, they've been treating only a very small number of patients out of the gate to get familiarity with the drug, to get familiarity with the process, to make sure that the access process isn't cumbersome. That's what we're focused on now, is to make sure that that process is streamlined by working very closely with these HCPs so that they gain that familiarity very quickly. We're taking other initiatives too, which we could talk about, like Quick Start programs. Quick Start programs are something that we initiated right from the beginning, but we're now expanding. Why are we expanding it?

Because we want to make sure that patients that get prescribed TRYNGOLZA get on the drug as fast as possible, because the experience by both the HCPs as well as the patients has been remarkably positive.

If we can get those patients while we work through an initial medical exception process, which takes longer with a new drug, a new class for payers, we can get them onto medicine as fast as possible. That experience is going to translate to deeper and deeper prescriptions being written by physicians because the experience has been so positive.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Understood. Now, I want to tackle this on multiple fronts. I think one of the things that is kind of a lesson for me too is, a payer can say, "I've given you broad access," but they can make it a pain to really get access to the medication, right? If we look at some of your insurance policies right now, you're 100% right. Like, above 550, history of pancreatitis. I mean, it's not like you look at the criteria in terms of being eligible and say, "This is particularly onerous." It doesn't look like that. But then the nuance is, okay, what do I need to actually get on TRYNGOLZA? I need to try maybe background therapies. I need to make sure that I'm on an optimized fibrate or an optimized fish oil.

Sometimes patients get on incretins and then they'll be at 700, they go to 500, and then a payer will say, "Well, we've solved the problem," right? So there's this kind of false dynamic of broad access, but ease is a different thing. How much is your team working on really improving conversion time? Because I think to your point too, if you look at your clinical data, many of these patients tried background therapy. There's a reason why they're not controlled, but I don't think the plans necessarily recognize that, and they kind of give these doctors and patients, you have to run through hoops, right? Do you think that is an issue, and is there a timeline to maybe improve that for TRYNGOLZA?

Brett Monia
CEO, Ionis

No question. We have a lot of activities underway to speed up the process from intent to treat, prescription writing, and covered patient. That's all going well. A couple of points I want to make to your question. One is, patients do have to be on a, have had to try a triglyceride-lowering agent to be eligible for TRYNGOLZA for payers. Not for the label, but for payers. But remember I mentioned those high-risk patients in my intro comments, that that's nearly 1 million people that are at very high risk for acute pancreatitis. Most of those patients are already on those generic drugs,

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Right.

Brett Monia
CEO, Ionis

Because they're in such bad condition. So we don't have to go through that hurdle. They're already on the medicines. For new patients that are new to, or just diagnosed, sure, they have to go through that process. That'll take three to six months to go through that process. But really, we're focused on those high-risk patients, the majority of which are already on generic drugs ineffectively. Second, payer coverage. We've actually been very pleased with the progress we've made in getting TRYNGOLZA into formularies with payers to date. After the first quarter of the launch, we had 34% of commercial lives covered, and those patients are being covered to label. That means that they're not being restricted to just the high-risk patient population or other segments of the patient population.

They are being covered to label, which means if you have triglyceride s 500 and above, regardless of history of acute pancreatitis, they are being covered. We are very pleased with that process to date. That is going to grow. That coverage is going to increase this year, and it is going to increase next year, and next year we expect to then have Medicare contracts in place. This is moving in the right direction. We are very pleased with where we are headed for this. What are we doing to speed up the process, to your question? It is not unusual for cardiologists to take time to be able to get comfortable with a new medicine, a new category for treatment. One of the things that we understand and we have seen success based on is calling those docs more often, right?

Getting in front of them and making sure that they understand the urgency to treat.

The urgency to treat. Not waiting for the next appointment by your patient and then measure their TGs and then get them off a treatment, but push those physicians to bring those patients in sooner, to get them on drug, to get them out of a risk for a potentially fatal acute pancreatitis attack. The other thing we are doing is not just the push, but the pull, right? Patient education. Do you know your triglyceride levels? Do you know that there is a medicine now that is available to treat effectively severely elevated triglyceride s? That is through campaigns like digital, omnichannel, those kinds of things to get to patients. Do you know your triglyceride s? There are a lot of learnings in the first few months of the launch, and I think we are making really good progress.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Understood. You talked about on the call, and even you alluded this in your opening remarks, the Quick Start program. Can you help us define who are the patients where this Quick Start program really helps? Is this someone where they want to get on therapy, a doctor has identified them, they are in the funnel, let us put it that way.

Brett Monia
CEO, Ionis

Yeah.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

It is just taking a long time to get coverage. Is it that they have to get through getting on background medication, right? Who is the patient who benefits from the Quick Start program? Can you kind of quantify with, I know you have not given exact numbers of people in the funnel, but even from a percentage perspective, the kind of demand that you have seen out of the gate, what percentage of that demand do you think you would be unable to convert to paid scripts if you actually had a Quick Start program in place out of the gate?

Brett Monia
CEO, Ionis

Well, one of the purposes, the main goals of the Quick Start program is, as I mentioned earlier, to get patients onto medicine and get that experience, which has been uniformly positive, as quickly as possible. The experience on the process to get them on covered drug or to get them onto drug and then covered drug, that makes sure that process, they see that that process is very smooth, streamlined, and efficient, and also the clinical experience. When you see your triglyceride s plummet in many cases, to normal levels, to get that process, get that experience in place, because that's going to just lead to deeper and deeper prescription writing, right? Once a physician sees their patient is doing so well, they're going to write deeper. I mean, a lot of these physicians are managing 50, 60, 70, 100 patients, but they're only prescribing a handful until they get that experience.

That's a big component to the purpose of the Quick Start program, is to get them that experience first, because their experience is positive. Which patients? It's going to be the high-risk patients that'll benefit the most.

I mean, all patients will, but those high-risk patients will benefit the most from the Quick Start program because the process to get to the treatment is faster because they're already on generic triglyceride-lowering drugs ineffectively, we don't have to go through that hurdle. The Quick Start program is only designed to offer a month or two of treatment before they get onto covered drugs, it's not indefinite.

It is a defined, finite period of time that they're going to stay on drug. We are very pleased with the conversion to paid drug, to commercial drug, once they complete the Quick Start program. It's still in the works. We have relaxed some of the criteria to get patients onto Quick Start programs faster, and we think that that's early signs are quite encouraging.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Understood. You mentioned high risk, and look, I am in total agreement with you. I think there is a clear place for this drug. I have been surprised doctors wouldn't call. If I was a cardiologist, I would be calling up people and saying, "You need to get this under control." But I feel like there is investor appetite. How do you stratify high risk, right? Because you could say on label, it is 2 million to 3 million. If we then cut it to, let us say, above 500 or 880 at risk, you can get to, let us say, 1 million, right? Then you cut it to prior history of AP, that gets to 50 to 80.

When we have done some doc calls recently, I sense that docs stratify maybe even more, where it is not even just prior history of AP, it might be how recently that AP event was, or were there multiple pancreatitis events, right? When you think about, it is not like you have a massive cardiovascular sales force, you have been really efficient here. What have you learned in your early metrics about where there has been the highest rate of conversion, right? You go again, like the 2 million, the 1 million, the 50,000 to 80,000 versus maybe it is recent prior AP or multiple prior AP. What have we learned out of the gate?

Brett Monia
CEO, Ionis

That is exactly right. Physicians are absolutely prioritizing patients at the highest risk, in their view, what is the highest risk, to get onto TRYNGOLZA first. That is exactly what we expected, and that is why we focused on the high-risk patient population out of the gate to focus on for getting patients onto TRYNGOLZA. There are about up to nearly 1 million people in the U.S. that are high risk for acute pancreatitis due to severely elevated triglycerides. To your point, Akash Tewari, what we are seeing, let me first say that we are seeing scripts across the board.

We are seeing scripts come in for patients that have no history of AP and are considered not high risk. That means their triglycerides are between 500 and 799, up to 800. Above 800 and/or a history of acute pancreatitis, if you have a history of acute pancreatitis, you are at high risk. If your triglycerides are above 800, above 880 in particular, you are considered high risk. We are seeing, of course, the majority of scripts coming in for those high-risk patients, but we are seeing it across the board. But you are right. What we are seeing prioritized are those patients that have had an acute pancreatitis event recently.

It's also still top of mind.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Yeah.

Brett Monia
CEO, Ionis

For physicians, right? I saw that patient last month. They were in the ICU for two weeks because they had an acute pancreatitis event and there was nothing I could do. I need to get that patient on drug.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Right.

Brett Monia
CEO, Ionis

So, it makes sense that they would do that first. Next would be those patients with a history of acute pancreatitis that still have their triglycerides through the roof. They maybe have had acute pancreatitis events a couple years ago. Those will be the next tier. Then there's the above 880 without a history of acute pancreatitis, and then there's the more general population. This is a really exciting market opportunity in that we know who the high-risk patients are that prescribers are going to treat most aggressively. And then we have the ability to expand and through steps, eventually even maybe getting to that lower-risk patient population that has no history of acute pancreatitis. And that's where we're managing, but we are focused on the high-risk patient population now, because we know that those are the priorities for HCPs.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

No, no. But when you say high, you mean recent AP or the million?

Brett Monia
CEO, Ionis

Both.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Okay. Got it.

Brett Monia
CEO, Ionis

Both. That's really up to the discretion of the physician. We think high risk means high risk.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Right.

Brett Monia
CEO, Ionis

For patients, whether they have had a recent AP event or whether they had one a year or two ago, because the recurrence of AP is known to increase substantially. Leave that up to the HCP to decide. We're focused on high risk. What we're seeing is that they are prioritizing those with a recent AP event.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Okay. That's very helpful. It's not like a slower start market building. These are not foreign concepts in cardiovascular medicine. There's no doubt about it. I think for the investor community, though, and this would be really helpful, sometimes it's like, you'll talk to a company, they're like, "We're sampling a ton out of the gate," right? So it's going to take time for us to convert. We have a high gross-to-net right now. It's going to improve over a certain period of time. We have a sense of patients getting into the funnel, the ones that are kind of converting out.

I think part of the frustration, I think investors had on Q3 is, we didn't really get a sketch of top of the funnel, in the funnel, and then, obviously with the guidance as implied flat Q3 to Q4, it gives you just a lot of uncertainty going into 2027 about really what the cadence is. Open-ended question, but really, I'd love to get your take. Help us understand, A, is there an appetite to give more metrics going into Q4 in 2027 so we can understand that conversion? Because again, people understand gross-to-net and free drug. That happens all the time. But I think the concern is when we didn't get those metrics, the worry is it's a demand problem, not a conversion problem, if that makes sense.

Brett Monia
CEO, Ionis

Yeah. Let me just level set by stating what the metrics were that we did provide, which I believe are very encouraging.

We will continue to provide these metrics at a minimum. First, we had more than 1,500 prescribers prescribe TRYNGOLZA by the end of September. That was three months after the sHTG approval. That's not bad. Second, we're beginning to see an uptick in those repeat prescribers, which is very important. As I mentioned before, they want to get experience with it, and then they're going to prescribe more deeply. 24% of prescribers at the end of September were prescribing more than one script for their patients, and we're seeing that growing. So we'll continue to share that. We also provided payer coverage. 34% of commercial lives with sHTG were being covered by payers by the end of September. That's a pretty good start for payer coverage, and we'll continue to provide that metric as well. Going forward, we're working through additional metrics we could provide.

We're 100% committed to providing as much information as we can to lend confidence how this launch is going, to understand how this launch is going, and to provide confidence that the launch is going to go well. We're still creating a brand new market, a new sector for treatment. It's going to require education and experience for this to really accelerate. We're pulling all the levers possible to make sure that happens.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Understood. I also will echo, sometimes too much is never a good thing either. But I think the other question is really into '27. You did say on the call, '27 is going to be an important growth year for TRYNGOLZA. Now, if you look at kind of consensus estimates going into next year, this is obviously pre the guidance cut, there was a big number, there was a big step up. I think there was a general sense, this is not a traditional CV launch. This is more of a, almost like ATTR, like faster launch out of the gate, an orphan CV launch in some ways. I know everyone kind of struggles with the label, right? Because high risk and then there's a target group. I'd love to get your take.

When we think about 2027 and we think about characterizing sHTG in the context of other CV launches, right? Does this feel more like an Entresto or PCSK9, or does this feel something more akin to an orphan CV launch where there's faster uptake out of the gate and it's more kind of plug and play?

Brett Monia
CEO, Ionis

Well, you said it, Akash. 2026 is going to be a very important year for TRYNGOLZA. We're excited about it, and we think that this is going to be a year in which we see meaningful growth in the launch for TRYNGOLZA. We still have a lot of work to do, to do all the things I already said, to build the market, to build experience, to build education, and we're taking all the steps we need to do that. We have not been able to find a good analog in the CV space that we can say, "Hey, that looks like an expectation for a TRYNGOLZA launch going forward." We're still building the market.

As we understand and we start to see things come into place, like a broader adoption and prescribing by HCPs, deeper prescribing by HCPs, payer coverage for TRYNGOLZA continuing to increase, Medicare coming on board, and so forth, I think we will be able to provide more metrics and a better understanding if there is an analog out there today. What we are 100% confident in is that this is a multi-billion dollar product opportunity, and TRYNGOLZA is the first to market to deliver the treatment that these patients need. And we are pulling all the stops to make sure that TRYNGOLZA maximizes value for all stakeholders.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Understood. We are out of time, and it is a shame because I know you have so much going on within Ionis, but I really do appreciate the time. Wonderful discussion.

Brett Monia
CEO, Ionis

Thanks.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Thank you.

Brett Monia
CEO, Ionis

Thanks, Akash. Have a great day.